RetinalGenix Technologies Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 2.15 million compared to USD 0.510643.
A New Patent Granted for an Affordable and Effective Device and Method To Detect Ocular And Systemic DiseasesPETALUMA, Calif., Feb. 22, 2024 RetinalGeniX™ Technologies Inc. today announced.
PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“ RetinalGeniX ” or the “Company”) today announced that it has been granted a patent by the United
RetinalGeniX Technologies Inc. announced that it has contracted with MEDsan Inc. to provide diagnostic testing services for its Institutional Review Board to conduct a study to personalize medical.
PETALUMA, Calif., Dec. 21, 2023 RetinalGeniX Technologies Inc. , today announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board. RetinalGeniX is an.